Confirm favorable treatment results of international studies.Relate (loco regional) tumor control, side effects and (inter current) death to geriatric questionnaires/condition, co-morbidity and usage of medication.
ID
Source
Brief title
Condition
- Breast neoplasms malignant and unspecified (incl nipple)
- Breast therapeutic procedures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Confirm favorable tumor control and cosmetic outcome (< 5% grade >2 toxicity, <
5% local recurrence (5yr), > 90% good/excellent cosmetic result).
Secondary outcome
Gathering QOL, geriatric and other information for modeling patient outcome.
EORTC QOL C30/ breast module, ACE 27, registration multi-pharmacy, geriatric
screening questionnaire (incl. GFI ,G8 and VES 13). Also digital pictures will
be made after 3 and 5 years for objective cosmetic results.
Background summary
The treatment policy for elderly patients with early stage breast cancer is
largely intuitive and is just partly based on evidence as these patients are
often not included in phase II/III studies. As a consequence a relative large
proportion is treated by breast ablation and sentinel node biopsy. Accelerated
partial breast irradiation (APBI) either by intra-operative or external beam
radiotherapy might be a good alternative for elderly patients offering less
treatment burden in a shortened treatment time and a limited chance of
recurrence. International studies using APBI claim equivalent tumor control and
cosmetic results compared to conventional fractionated radiotherapy.
The elderly patient is a complex patient due to the age, the (geriatric)
condition with frequent co-morbidity and usage of multiple medications. The
collection of information of these (geriatric) conditions in Dutch radiotherapy
centers will give us a solid base to construct algorithms to predict patient
outcome (tumor related, morbidity and intercurrent disease)
Study objective
Confirm favorable treatment results of international studies.
Relate (loco regional) tumor control, side effects and (inter current) death to
geriatric questionnaires/condition, co-morbidity and usage of medication.
Study design
registration study applying treatment modalities with proven efficacy in
international phase III studies in an elderly study population
Intervention: depending on the facilities of the centre either intra-operative
radiotherapy at lumpectomy (21 Gy 90% isodose, *ELIOT procedure*) or
postoperative external beam radiotherapy (3DCRT or IMRT, 10x3,4 Gy ICRU, 10
fractions in 2 weeks).
Study burden and risks
This registration study is aimed to confirm the favorable treatment results of
randomized international studies so tumor control and cosmesis will be
comparable with the conventional approach. As such the treatment will be less
extensive than routinely applied (lumpectomy instead of ablation; less
radiation treatments (1 intra-operative fraction or 10 external beam fractions
in 2 weeks instead of 25 in 5 weeks). The extra burden will be the
questionnaires and two digital pictures after 3 and 5 years to evaluate the
cosmetic result. The EORTC C30 and breast module are basic and need 5-10
minutes of time (at start, at the end of treatment and every half year
afterwards). The geriatric questionnaires (Groningen FI, G8 and VES 13) will
take approx. 10 minutes to complete and will be offered at start, at the end of
treatment and every half year. The co-morbidity and medication questionnaire
will be offered at start (5-10 minutes) and checked for changes afterwards. A
major effort will be done to convert the paper questionnaires to electronic
questionnaires to facilitate the practical implementation of this study and
future studies.
Burgemeester Banninglaan 1
Leidschendam 2262 BA
NL
Burgemeester Banninglaan 1
Leidschendam 2262 BA
NL
Listed location countries
Age
Inclusion criteria
Histological confirmed breast cancer (DCIS and invasive) ductal subtypes
T1-2 smaller than 30mm as determined by ultrasound
N0 on palpation and ultrasound examination
Unicentric, Unifocal disease (radiological), multifocal when limited within 2 cm of the index lesion)
Age * 60
Any hormonal receptor status, hormonal therapy allowed following Dutch treatment guidelines
Technically eligible for lumpectomy or radiotherapy
No contra indications for lumpectomy and sentinal node procedure
Written informed consent
Willing to fill out the QOL, geriatric- and co morbidity questionaires - if applicable
Exclusion criteria
Patients not eligible / fit for lumpectomy and sentinal node procedure
pT2 (>30mm), pT3 and pT4
Positive surgical margins
Multi centricity; multifocal (> 2cm from the index lesion)
Extensive intraductal carcinoma; lympho-vascular invasion
Previous treatment of ipsilateral breast tumor (DCIS or invasive)
Paget disease of the nipple
Cutaneous involvement
Distant metastases; > pN1a
Previous radiotherapy on the ipsilateral breast
neo adjuvant chemotherapy for current malignancy
Collagen diseases (systematic erythematosus lupus, scleroderma, dermatomyositis)
Psychiatric diseases or other that prevents signing of informed consent
Other neoplasm's in the last 5 year with exception of skin tumors (excl melanoma) and intraepthelial lesions of the cervix uteri
Design
Recruitment
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL32061.098.10 |